University of Washington

Abacus Bioscience, Inc.

Albany Medical College

Deborah Fuller

Edward A Clark

Che-Leung Law

David Baker

Michael J Gale

Aaron Arthur Chevalier

Amanda Mak

Merika Treants Koday

Lance Joseph Stewart

Daniel Adriano Silva Manzano

Edmund J Gosselin

Gabriel Jacob Rocklin

Christopher David Bahl

Jason Gilmore

Jorgen Nelson

Compositions including a CD180 binding ligand and a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpreS1/S2Ag), L-HBsAg, MHBsAg, S-HBsAg, or antigenic fragments or mutants thereof.

Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein

Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.

Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV core antigen

Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV PreS1 and/or PreS2, and/or s-HBsAg regions of the HBV envelope protein

Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen

An immunogenic fusion protein for use as a mucosal vaccine is provided, which includes: i) one or more FcyR1-binding domains; ii) one or more antigens from one or more infectious disease organisms; and iii) one or more FcRn-binding domains.

Multi-functional mucosal vaccine platform

Polypeptides that bind to viral hemagglotinin are disclosed and methods for their use in treating or limiting influenza infection, and diagnosing influenza infection.

De novo designed hemagglutinin binding proteins

Designed polypeptides having the amino acid sequence of SEQ ID NQ: 1 are described that bind with high affinity and selectivity to the influenza hemagglutinin protein, and which can be used for treating and/or limiting an influenza infection, as well as diagnosing an influenza infection and identifying candidate compounds for treating an influenza infection.

Enhanced influenza hemagglutinin binders

Growing community of inventors

Seattle, WA, United States of America

Deborah Fuller